Celltrion Reports 24 Week P-III Trial Results of CT-P42 (biosimilar, aflibercept) for Wet Age-Related Macular Degeneration and Diabetic Macular Edema
Shots:
- The company highlighted the 24wk. results from the P-III clinical trial of CT-P42, a biosimilar referencing Eylea. The results showed that CT-P42 met the predefined equivalence criteria of ±3 letters, and 2EPs of efficacy, safety, and immunogenicity also showed similar trends to Eyela
- Eylea is expected to reach substance patent expiration in the US in June 2023 and in the EU in May 2025. The company plans to complete the remaining P-III studies of CT-P42 and file for product license in the US and EU in 2023
- Additionally, the company also conducts a 52wk. trial in 348 patients for the treatment of DME in 13 countries, incl. Germany and Spain
Ref: KoreaBio | Image: Celltrion
Related News:- Celltrion Initiates P-III Study of CT-P42 (biosimilar- aflibercept)
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
